申请人:LILLY CO ELI
公开号:WO2020247429A1
公开(公告)日:2020-12-10
The present invention provides compounds of the Formula (I) wherein L is selected from the group consisting of -CH2NHCH2-, -CH2NH-, -NH-, -S-, -S(O)-, -S(O)2-, -O-, -OCH2-, -OCH2CH2O-, -NHSO2NH-, (II) and (III), or a pharmaceutically acceptable salt thereof; a compound of the formula: (IV), processes for preparing the compounds and their salts, a pharmaceutical composition, and methods of treating patients in need of such treatment.
本发明提供了式(I)化合物,其中L选自以下组:-CH2NHCH2-,-CH2NH-,-NH-,-S-,-S(O)-,-S(O)2-,-O-,-OCH2-,-OCH2CH2O-,-NHSO2NH-,(II)和(III),或其药物可接受的盐;式(IV)的化合物,制备这些化合物及其盐的过程,药物组合物,以及治疗需要此类治疗的病人的方法。